

ICD-10 Coordination and Maintenance Committee Meeting September 23-24, 2014 Diagnosis Agenda

Welcome and announcements Donna Pickett, MPH, RHIA Co-Chair, ICD-10 Coordination and Maintenance Committee

Diagnosis Topics:

Contents

Castleman Disease	9
David Fajgenbaum, MD, MSc	
Co-Founder & Executive Director, Castleman Disease Collaborative Network	
National Institutes of Health Stroke Scale	. 12
Cryopyrin-Associated Periodic Syndromes and Other Autoinflammatory Syndromes	. 16
Dental Terms	
Mastocytosis and Certain Other Mast Cell Disorders	. 20
Dyspareunia	
Incontinence	. 28
Difficulties with micturition	. 29
Irritable Bowel Syndrome with Constipation	. 30
Chronic Idiopathic Constipation	. 31
Observation and evaluation of newborns for suspected conditions ruled out	. 32
Gestational Carrier	. 34
Minimally Invasive Surgical Procedures Converted to Open	. 35
3rd Degree Laceration during delivery	. 38
Ectopic Pregnancy	. 40
Contraceptive Initial Encounter and Surveillance Codes	. 41
Ovarian Cyst Laterality	. 42
Supervision of Pregnancy with History of Ectopic or Molar Pregnancy	. 44
Sarcopenia	. 45
ICD-10-CM Tabular Addenda	. 47
ICD-10-CM Index Addenda	. 51

ICD-10 TIMELINE

A timeline of important dates in the ICD-10 process is described below:

September 23 –24, 2014	ICD-10 Coordination and Maintenance Committee meeting
	Those who wish to attend the ICD-10 Coordination and Maintenance Committee meeting must have registered for the meeting online by September 12, 2014. You must bring an official form of picture identification (such as a driver's license) in order to be admitted to the building.
	Webcast and Dial-In Information: The meeting webcast can be accessed at <u>http://www.cms.gov/live/</u> . Toll-free dial-in access is available for participants who cannot join the webcast. Phone: 1.877.267.1577; Meeting ID: 993 682 630. We encourage you to join early, as the number of phone lines is limited.
October 2014	Summary report of the Procedure part of the September 23, 2014 ICD-10 Coordination and Maintenance Committee meeting will be posted on the CMS webpage as follows:
	https://www.cms.gov/Medicare/Coding/ICD9ProviderDiagnostic Codes/meetings.html
	Summary report of the Diagnosis part of the September 24, 2014 ICD-10 Coordination and Maintenance Committee meeting report will be posted on NCHS homepage as follows: <u>http://www.cdc.gov/nchs/icd/icd9cm_maintenance.htm</u>
November 21, 2014	Deadline for receipt of public comments on proposed code revisions discussed at the September 23-24, 2014 ICD-10 Coordination and Maintenance Committee meetings for implementation on October 1, 2015.
January 16, 2015	Deadline for requestors: Those members of the public requesting that topics be discussed at the March 18–19, 2015 ICD-10 Coordination and Maintenance Committee meeting must have their requests submitted to CMS for procedures and NCHS for diagnoses by this date.
February 2015	Draft agenda for the Procedure part of the March 18, 2015 ICD-10 Coordination and Maintenance Committee meeting posted on CMS homepage as follows: <u>http://www.cms.gov/Medicare/Coding/ICD9ProviderDiagnosticCodes/meetings.h</u> <u>tml</u>

	ICD-10 Coordination and Maintenance Committee Meeting September 23-24, 2014
	Draft agenda for the Diagnosis part of the March 19, 2015 ICD-10 Coordination and Maintenance Committee meeting posted on NCHS homepage as follows: <u>http://www.cdc.gov/nchs/icd/icd9cm_maintenance.htm</u>
	Federal Register notice of March 18–19, 2015 ICD-10 Coordination and Maintenance Committee Meeting will be published.
February 13, 2015	On-line registration opens for the March 18–19, 2015 ICD-10 Coordination and Maintenance Committee meeting at: <u>https://www.cms.gov/apps/events/default.asp</u>
March 2015	Because of increased security requirements, those wishing to attend the March 18–19, 2015 ICD-10 Coordination and Maintenance Committee meeting must register for the meeting online at: <u>https://www.cms.gov/apps/events/default.asp</u>
	Attendees must register online by March 13, 2015; failure to do so may result in lack of access to the meeting.
March 18 – 19, 2015	ICD-10 Coordination and Maintenance Committee meeting.
April 17, 2015	Deadline for receipt of public comments on proposed code revisions discussed at the March 18–19, 2015 ICD-10 Coordination and Maintenance Committee meetings for implementation on October 1, 2015.
April 2015	Notice of Proposed Rulemaking to be published in the <u>Federal Register</u> as mandated by Public Law 99-509. This notice will include references to the complete and finalized FY 2016 ICD-10-CM diagnosis and ICD-10-PCS procedure codes. It will also include proposed revisions to the MS-DRG system based on ICD-10-CM/PCS codes on which the public may comment. The proposed rule can be accessed at:
	http://www.cms.gov/Medicare/Medicare-Fee-for-Service- Payment/AcuteInpatientPPS/index.html?redirect=/AcuteInpatientPPS/IPPS/list.as
	μ μ
April 2015	Summary report of the Procedure part of the March 18, 2015 ICD-10 Coordination and Maintenance Committee meeting will be posted on the CMS webpage as follows: <u>https://www.cms.gov/Medicare/Coding/ICD9ProviderDiagnosticCodes/meetings.</u> <u>html</u>
	Summary report of the Diagnosis part of the March 19, 2015 ICD-10 Coordination and Maintenance Committee meeting report will be posted on the NCHS webpage as follows: <u>http://www.cdc.gov/nchs/icd/icd9cm_maintenance.htm</u>

	ICD-10 Coordination and Maintenance Committee Meeting September 23-24, 2014
June 2015	Final addendum posted on web pages as follows: Diagnosis addendum - <u>http://www.cdc.gov/nchs/icd/icd10cm.htm</u> Procedure addendum - <u>http://cms.hhs.gov/Medicare/Coding/ICD10/index.html</u>
July 17, 2015	Deadline for requestors: Those members of the public requesting that topics be discussed at the September 22–23, 2015 ICD-10 Coordination and Maintenance Committee meeting must have their requests submitted to CMS for procedures and NCHS for diagnoses.
August 1, 2015	Hospital Inpatient Prospective Payment System final rule to be published in the Federal Register as mandated by Public Law 99-509. This rule will also include links to all the final codes to be implemented on October 1, 2015. This rule can be accessed at: <u>http://www.cms.gov/Medicare/Medicare-Fee-for-Service-</u> Payment/AcuteInpatientPPS/index.html?redirect=/AcuteInpatientPPS/IPPS/list.as
	<u>p</u>
August 2015	 Tentative agenda for the Procedure part of the September 22–23, 2015 ICD-10 Coordination and Maintenance Committee meeting will be posted on the CMS webpage at - <u>http://www.cms.gov/Medicare/Coding/ICD9ProviderDiagnosticCodes/meetings.h</u> <u>tml</u> Tentative agenda for the Diagnosis part of the September 22 –23, 2015 ICD-10 Coordination and Maintenance Committee meeting will be posted on the NCHS webpage at - <u>http://www.cdc.gov/nchs/icd/icd9cm_maintenance.htm</u> Federal Register notice for the September 22–23, 2015 ICD-10 Coordination and Maintenance Committee meeting will be published. This will include the tentative agenda.
August 14, 2015	On-line registration opens for the September 22-23, 2015 ICD-10 Coordination and Maintenance Committee meeting at: <u>https://www.cms.gov/apps/events/default.asp</u>
September 11, 2015	 Because of increased security requirements, those wishing to attend the September 22-23, 2015 ICD-10 Coordination and Maintenance Committee meeting must register for the meeting online at: https://www.cms.gov/apps/events/default.asp Attendees must register online by September 11, 2015; failure to do so may result in lack of access to the meeting.
September 22 –23, 2015	ICD-10 Coordination and Maintenance Committee meeting.

	ICD-10 Coordination and Maintenance Committee Meeting September 23-24, 2014
	Those who wish to attend the ICD-10 Coordination and Maintenance Committee meeting must have registered for the meeting online by September 11, 2015. You must bring an official form of picture identification (such as a driver's license) in order to be admitted to the building.
October 2015	Summary report of the Procedure part of the September 22–23, 2015 ICD-10 Coordination and Maintenance Committee meeting will be posted on the CMS webpage as follows:
	https://www.cms.gov/Medicare/Coding/ICD9ProviderDiagnosticCodes/meetings. html
	Summary report of the Diagnosis part of the September 22–23, 2015 ICD-10 Coordination and Maintenance Committee meeting report will be posted on NCHS homepage as follows: <u>http://www.cdc.gov/nchs/icd/icd9cm_maintenance.htm</u>
October 1, 2015	ICD-10-CM/PCS codes go into effect along with ICD-10 MS- DRGs
October 1, 2015	New and revised ICD-10-CM and ICD-10-PCS codes go into effect along with DRG changes. Final addendum posted on web pages as follows: Diagnosis addendum - <u>http://www.cdc.gov/nchs/icd/icd9cm_addenda_guidelines.htm</u> Procedure addendum – <u>http://www.cms.gov/Medicare/Coding/ICD10/</u>
October 16, 2015	Deadline for receipt of public comments on proposed code revisions discussed at the September 22-23, 2015 ICD-10 Coordination and Maintenance Committee meetings for implementation on April 1, 2016.
November 2015	Any new ICD-10 codes required to capture new technology that will be implemented on the following April 1 will be announced. Information on any new codes to be implemented April 1, 2016 will be posted on the following websites: http://www.cms.gov/Medicare/Coding/ICD10/ http://www.cdc.gov/nchs/icd/icd9cm_addenda_guidelines.htm
November 13, 2015	Deadline for receipt of public comments on proposed code revisions discussed at the September 22-23, 2015 ICD-10 Coordination and Maintenance Committee meetings for implementation on October 1, 2016.

Contact Information

Mailing address:

National Center for Health Statistics ICD-9-CM Coordination and Maintenance Committee 3311 Toledo Road, Room 2402 Hyattsville, Maryland 20782 Fax: (301) 458-4022

Comments on the diagnosis proposals presented at the ICD Coordination and Maintenance Committee meeting should be sent to the following email address: <u>nchsicd10CM@cdc.gov</u>

Donna Pickett	(301) 458-4434	
David Berglund	(301) 458-4095	
Cheryl Bullock	(301) 458-4297	
Lizabeth Fisher	(301) 458-4091	
Shannon McConn	nell-Lamptey (301) 458-4612	
Traci Ramirez	(301) 458-4454	

NCHS Classifications of Diseases web page: <u>http://www.cdc.gov/nchs/icd.htm</u> Please consult this web page for updated information.

Partial Code Freeze for ICD-9-CM and ICD-10

The ICD-9-CM Coordination and Maintenance Committee implemented a partial freeze of the ICD-9-CM and ICD-10 (ICD-10-CM and ICD-10-PCS) codes prior to the implementation of ICD-10. The partial freeze is scheduled to end one year after the implementation of ICD-10. There was considerable support for this partial freeze. On April 1, 2014, the Protecting Access to Medicare Act of 2014 (PAMA) (Pub. L. No. 113-93) was enacted, which said that the Secretary may not adopt ICD-10 prior to October 1, 2015. Accordingly, the U.S. Department of Health and Human Services issued a final rule on August 4, 2014 that changed the compliance date for ICD-10 from October 1, 2014 to October 1, 2015. The final rule also requires HIPAA covered entities to continue to use ICD-9-CM through September 30, 2015. Links to the final rule are provided at http://www.cms.gov/Medicare/Coding/ICD10/Statute_Regulations.html.

The partial freeze will be implemented as follows:

• The last regular, annual updates to both ICD-9-CM and ICD-10 code sets were made on October 1, 2011.

• On October 1, 2012, October 1, 2013, and October 1, 2014 there were only limited code updates to both the ICD-9-CM and ICD-10 code sets to capture new technologies and diseases as required by section 503(a) of Pub. L. 108-173.

• On October 1, 2015, there will be only limited code updates to ICD-10 code sets to capture new technologies and diagnoses as required by section 503(a) of Pub. L. 108-173. There will be no updates to ICD-9-CM, as it will no longer be used for reporting.

• On October 1, 2016 (one year after implementation of ICD-10), regular updates to ICD-10 will begin. The ICD-9-CM Coordination and Maintenance Committee will continue to meet twice a year during the partial freeze. At these meetings, the public will be asked to comment on whether or not requests for new diagnosis or procedure codes should be created based on the criteria of the need to capture a new technology or disease. Any code requests that do not meet the criteria will be evaluated for implementation within ICD-10 on and after October 1, 2016 once the partial freeze has ended.

Continuing Education Credits

Continuing education credits may be awarded by the American Academy of Professional Coders (AAPC) or the American Health Information Management Association (AHIMA) for participation in CMS/NCHS ICD-10 Coordination and Maintenance (C&M) Committee Meeting.

Continuing Education Information for American Academy of Professional Coders (AAPC)

If you plan to attend or participate via telephone the ICD-10 Coordination and Maintenance (C&M) Committee Meeting, you should be aware that CMS /NCHS do not provide certificates of attendance for these calls. Instead, the AAPC will accept your printed topic packet as proof of participation. Please retain a your topic packet copy as the AAPC may request them for any conference call you entered into your CEU Tracker if you are chosen for CEU verification. Members are awarded one (1) CEU per hour of participation.

Continuing Education Information for American Health Information Management Association (AHIMA)

AHIMA credential-holders may claim 1 CEU per 60 minutes of attendance at an educational program. Maintain documentation about the program for verification purposes in the event of an audit. A program does not need to be pre-approved by AHIMA, nor does a CEU certificate need to be provided, in order to claim AHIMA CEU credit. For detailed information about AHIMA's CEU requirements, see the Recertification Guide on AHIMA's web site.

Please note: The statements above are standard language provided to NCHS by the AAPC and the AHIMA. If you have any questions concerning either statement, please contact the respective organization, <u>not NCHS</u>.

Castleman Disease

Specific codes for Castleman disease have been proposed by the Scientific Advisory Board of the Castleman Disease Collaborative Network.

Castleman disease describes a group of related lymphoproliferative disorders involving proliferation of morphologically benign lymphocytes due to excessive proinflammatory hypercytokinemia, most notably of interleukin-6. The NIH Office of Rare Disease Research, the American Cancer Society, and Orphanet all recognize and define Castleman disease as a lymphoproliferative disorder with varying clinical features that affects the lymph nodes and related tissues. Castleman disease is diagnosed when lymph node histopathology reveals regression of germinal centers, abnormal vascularity, and a range of hyaline vascular changes and/or polytypic plasma cell proliferation. It can occur in a single lymph node region (unicentric) or in multiple lymph node regions (multicentric). Clinical features and management vary significantly based on this distinction.

Unicentric Castleman disease (UCD) presents as a localized disease and mild symptoms are usually the result of enlarged or bulky lymph nodes. Based on limited epidemiological data, it has been estimated to account for approximately 90% of cases and have an excellent prognosis with surgical excision.

Multicentric Castleman disease (MCD) patients often demonstrate intense episodes of systemic inflammatory symptoms, polyclonal lymphocyte and plasma cell proliferation, autoimmune manifestations, and organ system impairment. Human Herpes Virus 8 (HHV-8, or Kaposi's Sarcoma Herpes Virus, KSHV) is etiologically responsible for MCD in patients with the plasmacytic or plasmablastic variants, which occurs most commonly in the setting of HIV-infection or other cause of immunosuppression, such as transplantation. This distinct form of multicentric Castleman disease is called HHV-8-associated MCD (also known as KSHV-associated MCD). UCD and all other cases of MCD are considered idiopathic since these cases are not caused by HHV-8 or any other known etiologic agent. HHV-8-negative MCD, also called "idiopathic MCD" (iMCD), and HHV-8-associated MCD require different therapeutic approaches, which further warrant their separation into unique categories. The specific types of MCD for which codes are proposed are briefly discussed further below.

HHV-8-associated MCD is characterized by lymphadenopathy, hepatosplenomegaly, anemia, thrombocytopenia, hypoalbuminemia, hypergammaglobinemia, and elevated C-reactive protein. Disease pathophysiology is associated with elevated serum levels of interleukin-6, an HHV-8 encoded homologue, viral interleukin-6, and interleukin-10. Diagnosis requires a biopsy demonstrating appropriate pathology and demonstrating HHV-8 encoded Latent Associated Nuclear Antigen (LANA) by immunohistochemistry. Symptomatic patients generally have elevated levels of HHV-8 detected in the peripheral blood by quantitative PCR (qPCR).

Patients with iMCD (HHV-8-negative MCD) demonstrate similar features to HHV-8-assocated MCD, but no HHV-8 can be found in the lymph node biopsy by staining for HHV-8 encoded LANA. HHV-8 is not detected in the blood by qPCR. In addition, these patients are almost always HIV negative. Like HHV-8 associated MCD, iMCD is a disseminated condition affecting multiple sites and is less common and more aggressive than UCD. The clinical features range from waxing and waning mild lymphadenopathy with B-symptoms to more severe cases involving intense inflammation, hepatosplenomegaly, vascular leak syndrome with anasarca, pleural effusions, and ascites, organ failure, and even death. Acute episodes can display significant clinical overlap with acute viral illnesses and autoimmune diseases. Laboratory findings commonly include anemia, elevated erythrocyte sedimentation rate, C-reactive protein, IL-6, vascular endothelial growth factor (VEGF), and fibrinogen; positive anti-nuclear antibody, anti-erythrocyte autoantibodies, and anti-platelet antibodies; and

proteinuria, hypoalbuminemia, polyclonal marrow plasmacytosis, polyclonal hypergammaglobulinemia, and thrombocytosis or thrombocytopenia.

One 2014 study estimated the incidence of Castleman disease to be in the range of 6300 to 7500 new cases per year in the US, and prior prevalence estimates have been in the range of 30,000 to 100,000 existing cases in the US (Munshi 2014). While rare, Castleman disease is more common than many other disorders, including many for which specific ICD codes have previously been created. Kaposi's sarcoma is also rare, and is caused by the same virus as some Castleman disease cases, HHV-8, or KSHV. Kaposi's sarcoma is coded to category C46, with specific codes for the site.

The Scientific Advisory Board of the Castleman Disease Collaborative Network recommends creation of four unique codes for Castleman disease, to support detailed tracking of the different types. Since it is a rare disorder, an alternative of only creating one code is also presented as an option.

References

Munshi N, et al. *Leuk Lymphoma*. 2014 Aug 13:1-32. Use of a Claims Database to Characterize and Estimate the Incidence Rate for Castleman's Disease. <u>http://www.ncbi.nlm.nih.gov/pubmed/25120049</u>

Option #1

	D47 Other neoplasms of uncertain behavior of lymphoid, hematopoietic and related tissue		
		-	ecified neoplasms of uncertain behavior of lymphoid, hematopoietic and d tissue
New subcategory		D47.Z2	Castleman disease
New code			D47.Z21 Unicentric Castleman disease
New code			D47.Z22 HHV-8-associated multicentric Castleman disease Human herpes virus 8-associated multicentric Castleman disease Kaposi sarcoma herpes virus associated multicentric Castleman disease KSHV-associated multicentric Castleman disease
New code			D47.Z23 HHV-8-negative multicentric Castleman disease Idiopathic multicentric Castleman disease
New code			D47.Z29 Castleman disease, unspecified

Option #2	
	TABULAR MODIFICATIONS
	D47 Other neoplasms of uncertain behavior of lymphoid, hematopoietic and related tissue
	D47.Z Other specified neoplasms of uncertain behavior of lymphoid, hematopoietic and related tissue
New code	D47.Z2 Castleman disease
	Code also if applicable human herpesvirus 8 infection (B10.89)
	INDEX MODIFICATIONS
	Disease
Add	Castleman (unicentric) (multicentric) D47.Z2
	HHV-8-associated (see also Herpesvirus, human, 8) D47.Z2

National Institutes of Health Stroke Scale

The National Institutes of Health Stroke Scale (NIHSS) is a systematic assessment tool to evaluate and document neurological status and stroke severity. This assessment tool is a 15-item examination that measures the patient's clinical status in areas including but not limited to level of consciousness, facial palsy, best gaze, motor skills, limb ataxia, language and visual fields. A certain number of points are given for each impairment and a maximum score of 42 represents the most severe and devastating stroke.

The NIHSS has been shown to predict mortality in acute ischemic stroke patients in several prior studies and its use is supported by evidence based guidelines.

A recent study showed that the initial NIHSS provides substantial prognostic information regarding 30-day mortality risk in Medicare beneficiaries with acute ischemic stroke. This study concluded that the NIHSS as an index of stroke severity is a very strong discriminator of 30-day mortality risk in acute ischemic stroke even in the absence of other clinical information.

Another study showed that many patients not given intravenous recombinant tissue plasminogen activator (IV rtPA) because of mild or rapidly improving stroke symptoms had poor hospital discharge outcomes. The initial NIHSS score was a strong predictor of outcome, with a graded relation between higher NIHSS score and a lower likelihood of discharge to home or independent ambulation among those with mild or improving ischemic stroke.

Based on these findings, there is significant value in the creation of ICD-10-CM codes for the NIHSS. At the present time there are no ICD-10-CM codes that capture the NIHSS score. This is a unique opportunity to address a critical gap by which to collect NIHSS score for patients. It is also anticipated that the Joint Commission will begin to collect NIHSS score as a measure of its Comprehensive Stroke Center (CSC) accreditation program.

While not required, the NIHSS score is recorded on a voluntary basis by hospitals participating in programs such as the American Heart Association's Get With The Guidelines-Stroke program, the Paul Coverdell National Acute Stroke Registry, or other state initiatives.

Given that the NIHSS score is a predictor of outcomes, the American Stroke Association, American Academy of Neurology, American Association of Neurological Surgeons and Congress of Neurological, American College of Emergency Physicians, American Society of Neuroradiology, National Association of EMS Physicians, Centers for Disease Control and Prevention (Paul Coverdell National Acute Stroke Program, Division for Heart Disease and Stroke Prevention), National Stroke Association, Neurocritical Care Society, The Office of the National Director of Neurology of the Department of Veterans Affairs, Society of NeuroInterventional Surgery and the Stroke Belt Consortium are requesting the creation of ICD-10-CM codes that would allow for the capture of NIHSS score of the severity of the stroke as measured in the initial patient evaluation at the hospital.

Two options are presented in this proposal. Option #1 provides ICD-10-CM codes for each score. It provides more detailed reporting and allows maximum manipulation of the data. The requestors indicate this is an important capability given the unpredictability of how scientific advances might move the treatment line for patients with CVA. Option #2 provides ICD-10-CM codes for a range of diagnostic scores of the NIHSS.

TABULAR MODIFICATIONS

R29 Other symptoms and signs involving the nervous and musculoskeletal systems

Option #1

New subcategory R29.7	National Institutes	of Health Stroke Scale (NIHSS) Score
	Code first Cerebral	infarction (I63)
New sub-sub category	R29.70 NIHSS scor	re 0-9
New code	R29.700	NIHSS score 0
New code	R29.701	NIHSS score 1
New code	R29.702	NIHSS score 2
New code	R29.703	NIHSS score 3
New code	R29.704	NIHSS score 4
New code	R29.705	NIHSS score 5
New code	R29.706	NIHSS score 6
New code	R29.707	NIHSS score 7
New code	R29.708	NIHSS score 8
New code	R29.709	NIHSS score 9
New sub-sub category	R29.71 NIHSS scor	re 10-19
New code	R29.710	NIHSS score 10
New code	R29.711	NIHSS score 11
New code	R29.712	NIHSS score 12
New code	R29.713	NIHSS score 13
New code	R29.714	NIHSS score 14
New code	R29.715	NIHSS score 15
New code	R29.716	NIHSS score 16
New code	R29.717	NIHSS score 17
New code	R29.718	NIHSS score 18
New code	R29.719	NIHSS score 19

New sub-sub category	R29.72 NIHSS score 2	0-29
New code	R29.720	NIHSS score 20
New code	R29.721	NIHSS score 21
New code	R29.722	NIHSS score 22
New code	R29.723	NIHSS score 23
New code	R29.724	NIHSS score 24
New code	R29.725	NIHSS score 25
New code	R29.726	NIHSS score 26
New code	R29.727	NIHSS score 27
New code	R29.728	NIHSS score 28
New code	R29.729	NIHSS score 29
New sub-sub category	R29.73 NIHSS score 30-	-39
New code	R29.730	NIHSS score 30
New code	R29.731	NIHSS score 31
New code	R29.732	NIHSS score 32
New code	R29.733	NIHSS score 33
New code	R29.734	NIHSS score 34
New code	R29.735	NIHSS score 35
New code	R29.736	NIHSS score 36
New code	R29.737	NIHSS score 37
New code	R29.738	NIHSS score 38
New code	R29.739	NIHSS score 39
New sub-sub category	R29.74 NIHSS score 40-	42
New code	R29.740	NIHSS score 40
New code	R29.741	NIHSS score 41
New code	R29.742	NIHSS score 42

Option #2:

New subcategory	R29.7 National Institutes of Health Stroke Scale (NIHSS) Score		
	<u>Code first</u> Cerebral infarction (I63)		
New Code	R29.71	Initial NIHSS Score 0–1	
New Code	R29.72	Initial NIHSS Score 2-4	
New Code	R29.73	Initial NIHSS Score 5-7	
New Code	R29.74	Initial NIHSS Score 8–12	
New Code	R39.75	Initial NIHSS Score 13–17	
New Code	R39.76	Initial NIHSS Score 18–21	
New Code	R29.77	Initial NIHSS Score 22–42	

I63 Cerebral infarction

New note Use additional code, if known, to indicate National Institutes of Health Stroke Scale (NIHSS) score (R29.7xx).

Cryopyrin-Associated Periodic Syndromes and Other Autoinflammatory Syndromes

A proposal to add codes for Cryopyrin-Associated Periodic Syndromes (CAPS) and other autoinflammatory syndromes was presented at the March 2014 C&M meeting. There was a request for creation of new ICD-10-CM codes for CAPS, including familial cold autoinflammatory syndrome, Muckle-Wells syndrome, and Neonatal Onset Multisystemic Inflammatory Disorder (NOMID), from Sobi, a biopharmaceutical company. Previous comments related to these being rare conditions, and raised concerns about adding specific codes for a number of rare conditions. Familial Mediterranean fever (FMF) has been classified to amyloidosis, but does not always cause amyloidosis. Previous comments support moving FMF. This revised proposal shows the option of creating a smaller number of new codes, which could each serve to include multiple disorders. This would also allow for future expansion, if needed.

The autoinflammatory syndromes are a group of relatively recently understood disorders, which involve problems with immune system regulation, with manifestations related to systemic inflammation. These disorders generally involve recurrent episodes of fever, rash, and serositis, with lymphadenopathy and musculoskeletal involvement.

	E85	Amyloidosis
Delete		E85.0 Non-neuropathic heredofamilial amyloidosis Familial Mediterranean fever
	L50	Urticaria
Add		L50.2 Urticaria due to cold and heat Excludes2: Familial cold urticaria (M04.2)
New section		Autoinflammatory syndromes (M04)
New Category	M04	Autoinflammatory syndromes Excludes2: Crohn's disease (K50)
New code		M04.1 Periodic fever syndromes Familial Mediterranean fever Hyperimmunoglobin D syndrome Mevalonate kinase deficiency Tumor necrosis factor receptor associated periodic syndrome [TRAPS]

	ICD-10 Coordination and Maintenance Committee Meeting September 23-24, 2014
New code	M04.2 Cryopyrin-associated periodic syndromes Chronic infantile neurological, cutaneous and articular syndrome [CINCA] Familial cold autoinflammatory syndrome Familial cold urticaria Muckle-Wells syndrome
	Neonatal onset multisystemic inflammatory disorder [NOMID]
New code	M04.8 Other autoinflammatory syndromes Blau syndrome Deficiency of interleukin 1 receptor antagonist [DIRA] Majeed syndrome Periodic fever, aphthous stomatitis, pharyngitis, and adenopathy syndrome [PFAPA] Pyogenic arthritis, pyoderma gangrenosum, and acne syndrome PAPA syndrome
New code	M04.9 Autoinflammatory syndrome, unspecified

Dental Terms

The Harvard School of Dental Medicine previously submitted a proposal to add a number of dental terms to ICD-10-CM, which were considered in September 2013. Based on input from the American Dental Association, this modified set of changes is now being proposed, and will supersede the previous proposal.

It is proposed to add new codes for reversible pulpitis, and irreversible pulpitis, without inclusion terms.

At code K05.5, Other periodontal diseases, it is proposed to add an inclusion term for narrow gingival width (of periodontal soft tissue),

It is proposed to add a new code K06.3, Horizontal alveolar bone loss.

It is proposed to expand K08.8, creating new codes K08.81, Primary occlusal trauma, and K08.82, Secondary occlusal trauma, along with new code K08.89, Other specified disorders of teeth and supporting structures

	K02 Dental caries			
	Includes:			
Add	Caries of dentine			
Add	Early childhood caries			
Add	Pre-eruptive caries			
Add	Recurrent caries (DEJ) (Enamel) (to the pulp)			
	K02.5 Dental caries on pit and fissure surface			
Add	K02.52 Dental caries on pit and fissure surface penetrating into dentin Primary dental caries, cervical origin			
	K04 Diseases of pulp and periapical tissues			
Delete	K04.0 Pulpitis Irreversible pulpitis Reversible pulpitis			
New code	K04.01 Reversible pulpitis			
New code	K04.02 Irreversible pulpitis			

	ICD-10 Coordination and Maintenance Committee Meeting September 23-24, 2014		
	K05 Gingivitis and periodontal diseases		
	K05.0 Acute gingivitis		
Add	K05.00 Acute gingivitis, plaque induced Plaque induced gingival disease		
Add	K05.1 Chronic gingivitis Pregnancy associated gingivitis		
Add Add	K05.5 Other periodontal diseases Combined periodontic-endodontic lesion Narrow gingival width (of periodontal soft tissue)		
	K06 Other disorders of gingiva and edentulous alveolar ridge		
New code	K06.3 Horizontal alveolar bone loss		
	K06.8 Other specified disorders of gingiva and edentulous alveolar ridge		
Add	Vertical ridge deficiency		
	K08 Other disorders of teeth and supporting structures		
	K08.8 Other specified disorders of teeth and supporting structures Enlargement of alveolar ridge NOS Irregular alveolar process Toothache NOS		
New code	K08.81 Primary occlusal trauma		
New code	K08.82 Secondary occlusal trauma		
New code	K08.89 Other specified disorders of teeth and supporting structures Enlargement of alveolar ridge NOS Insufficient anatomic crown height Insufficient clinical crown length Irregular alveolar process Toothache NOS		

Mastocytosis and Certain Other Mast Cell Disorders

Due to the many recent advances in mast cell disorder research, the American Academy of Allergy, Asthma, and Immunology (AAAAI) Mast Cell Disorders Committee, together with The Mastocytosis Society, Inc., recognized the urgency of developing an updated code hierarchy for mastocytosis. Revised and cohesive codes for these disease conditions are not only warranted, but necessary and vital to patients whose disease could otherwise go unrecognized or untreated.

Broadly, mastocytosis can be divided into cutaneous and systemic forms. Symptoms can be due to release of substances such as histamine, and can include headaches, dizziness, flushing, tachycardia, hypotension, syncope, nausea, vomiting, abdominal pain, and diarrhea.

As a result of significant advances in the study of neoplastic mast cells and their morphology, phenotype and genetic characteristics, a consensus classification for Mastocytosis was proposed and adopted by the World Health Organization (WHO) in 2001. Mastocytosis comprises a set of disorders involving abnormal proliferation and accumulation of clonal mast cells in one or multiple organ systems.

Cutaneous Mastocytosis (CM) is diagnosed by the presence of typical skin lesions and a positive skin biopsy demonstrating characteristic clusters of mast cells. This category includes Urticaria Pigmentosa (UP)/Maculopapular Cutaneous Mastocytosis (MPCM), Telangiectasia Macularis Eruptiva Perstans (TMEP), Diffuse Cutaneous Mastocytosis (DCM), and Solitary Mastocytoma. Most cases of Pediatric Mastocytosis fall into one of these categories and may or may not include symptoms of systemic mast cell activation as a result of mediators released from the skin. In children, cutaneous lesions can be expected to spontaneously regress before or at puberty 70-75% of the time, while the remaining 25-30% will develop into Indolent Systemic Mastocytosis or another variant of Systemic Mastocytosis.

The WHO criteria requires that for a diagnosis of Systemic Mastocytosis (SM) to be established, one major criterion and one minor criterion or three minor criteria must be fulfilled. The 2001 WHO criteria can be summarized as follows:

Major: Multifocal dense infiltrates of mast cells (MCs) (> 15 MCs in aggregate) in tryptase stained biopsy sections of the bone marrow or other extracutaneous organ Minor:

- More than 25% of MCs in bone marrow or other extracutaneous organ(s) show abnormal morphology (i.e. are atypical MC type 1 or are spindle–shaped MCs) in multifocal lesions in histologic examination
- KIT mutation (KIT is a tyrosine kinase receptor) at codon 816b in extracutaneous organ(s) (in most cases bone marrow cells are examined)
- KIT+MCs in bone marrow show aberrant expression of CD2 and/or CD25
- Serum total tryptase > 20 ng/mL (does not count in patients who have ANHMD-type disease; AHNMD is associated (clonal) hematologic non-mast cell lineage disease).

Mastocytosis and mast cell neoplasms have been classified to a few different categories in ICD. Certain types are malignant. Code C96.2, Malignant mast cell tumor, includes aggressive systemic mastocytosis and mast cell sarcoma. It is proposed to expand and create specific codes for these disorders. Also, it is proposed to change the title for C96.2, to Malignant mast cell neoplasm. Mast cell leukemia is classified to C94.3.

The default for mastocytosis has been Q82.2, Mastocytosis, in category Q82, Other congenital malformations of skin. However, certain types of mastocytosis and mast cell neoplasms are classified in the ICD with neoplasms of uncertain behavior. It is proposed to create new subcategories and codes for certain of these at category D47, Other neoplasms of uncertain behavior of lymphoid, hematopoietic and related tissue, and subcategory D47.0, along with changing the title of D47.0 to Mast cell neoplasms of uncertain behavior (replacing "tumors" with "neoplasms," and moving histiocytic neoplasms elsewhere). With the difference in prognosis between pediatric and adult mastocytosis, as well as cutaneous and systemic mastocytosis, it has been proposed to create separate subcategories for these. It should be noted that a diagnosis of primary mast cell activation syndrome would not need to be coded separately (with the new proposed codes from March 2014), with these new proposed codes. Additional Excludes1 notes are proposed to be created with the proposed mast cell activation syndrome codes, to clarify this. It is proposed that new default codes for mastocytosis be created at D47.

It is proposed that code Q82.2, Mastocytosis, be retitled, and expanded. Cases with onset in the newborn or neonatal period will be classified here. For clarity, that the title be changed to Pediatric cutaneous mastocytosis of newborn onset. Expansion is proposed to include codes for Urticaria pigmentosa of newborn onset, Diffuse cutaneous mastocytosis of newborn onset, Solitary mastocytoma of newborn onset, and Other cutaneous mastocytosis of newborn onset, as well as an unspecified code.

References

American Academy of Allergy, Asthma and Immunology Mast Cell Disorders Committee and The Mastocytosis Society, Inc. ICD-10-CM Coding Proposal, Mastocytosis. Direct communication, received for Sept. 2014 ICD C&M Meeting.

Hogan DJ, Mastrodomenico CM. "Mastocytosis." Medscape, EMedicine, online, retrieved Sep. 2014. http://emedicine.medscape.com/article/1057932-overview

Urticaria pigmentosa. Medline Plus, online, retrieved Sep. 2014. http://www.nlm.nih.gov/medlineplus/ency/article/001466.htm

Mastocytosis. NIAID, online, retrieved Sep. 2014. http://www.niaid.nih.gov/topics/mastocytosis/pages/default.aspx

	C96	Other and unspecified malignant neoplasms of lymphoid, hematopoietic and related tissue		
Revise Delete		C96.2 Malignant mast cell <u>neoplasm</u> tumor Aggressive systemic mastocytosis Mast cell sarcoma		
New code		C96.	20 Malignant mast cell neoplasm, unspecified	
New code		C96.	21 Aggressive systemic mastocytosis	
New code		C96.	22 Mast cell sarcoma	
New code		C96.	29 Other malignant mast cell neoplasm	

D47 Other neoplasms of uncertain behavior of lymphoid, hematopoietic and related tissue

Revise Delete	D47.0	Histiocytic and mast- <u>Mast</u> cell <u>neoplasms</u> tumors of uncertain behavior Indolent systemic mastocytosis Mast cell tumor NOS Mastocytoma NOS		
Add Add Revise Add Delete		Mastocytoma NOS Excludes1: <u>congenital cutaneous mastocytosis (Q82.2-)</u> histiocytic neoplasms of uncertain behavior (D47.Z8) malignant mast cell <u>neoplasm</u> tumor (C96.2-) pediatric cutaneous mastocytosis of newborn onset (Q82.2-) <u>mastocytosis (congenital) (cutaneous) (Q82.2-)</u>		
New subcategory		D47.01 Pediatric	cutaneous mastocytosis	
New code		D47.010	Pediatric urticaria pigmentosa Pediatric maculopapular cutaneous mastocytosis Maculopapular cutaneous mastocytosis, unspecified Urticaria pigmentosa, unspecified Excludes1:congenital urticaria pigmentosa (Q82.21) urticaria pigmentosa with newborn onset (Q82.21)	
New code		D47.011	Pediatric diffuse cutaneous mastocytosis Excludes1:congenital diffuse cutaneous mastocytosis (Q82.22) diffuse cutaneous mastocytosis with newborn onset (Q82.22)	
New code		D47.012	Pediatric solitary mastocytoma Solitary mastocytoma, unspecified Excludes1:adult solitary mastocytoma (D47.028) pediatric solitary mastocytoma with newborn onset (Q82.23) extracutaneous mastocytoma (D47.097)	
New code		D47.018	Other pediatric cutaneous mastocytosis	
New code		D47.019	Pediatric cutaneous mastocytosis, unspecified	
New subcategory		D47.02 Adult cut	aneous mastocytosis	
New code		D47.020	Adult urticaria pigmentosa Adult maculopapular cutaneous mastocytosis Excludes1:urticaria pigmentosa NOS (D47.010) urticaria pigmentosa with newborn onset (Q82.21)	
New code		D47.021	Telangiectasia macularis eruptiva perstans	

ICD-10 Coordination and Maintenance Committee Meeting September 23-24, 2014			
New code	D47.028	Other adult cutaneous mastocytosis Adult solitary mastocytoma Adult diffuse cutaneous mastocytosis Excludes1:extracutaneous mastocytoma (D47.097) pediatric solitary mastocytoma with newborn onset (Q82.23) solitary mastocytoma NOS (D47.012)	
New code	D47.029	Adult cutaneous mastocytosis, unspecified	
New code	D47.03 Pediatric	systemic mastocytosis	
New subcategory	D47.04 Adult sys	temic mastocytosis	
	Excludes1	:aggressive systemic mastocytosis (C96.21) mast cell leukemia (C94.3-)	
New code	D47.041	Indolent systemic mastocytosis Isolated bone marrow mastocytosis	
New code	D47.042	Smoldering systemic mastocytosis	
New code	D47.043	Systemic mastocytosis, with an associated hematological non- mast cell lineage disease (SM-AHNMD) Code also associated hematological non-mast cell lineage disease, such as: acute myeloid leukemia (C92.6-, C92.A-) chronic myelomonocytic leukemia (C93.1-) essential thrombocytosis (D47.3) hypereosinophilic syndrome (D72.1) myelodysplastic syndrome (D46.9) myeloproliferative syndrome (D47.1) non-Hodgkin lymphoma (C82-C85) plasma cell myeloma (C90.0-) polycythemia vera (D45)	
New code	D47.048	Other systemic mastocytosis Other adult systemic mastocytosis	
New code	D47.049	Systemic mastocytosis, unspecified Adult systemic mastocytosis NOS	
New subcategory	D47.09 Other ma	st cell neoplasms of uncertain behavior	
New code	D47.090	Other mastocytosis Cutaneous mastocytosis NOS	

ICD-10 Coordination and Maintenance Committee Meeting September 23-24, 2014			
New code		D47.091 Mastocytosis, unspecified	
New code		D47.092 Other mastocytoma Extracutaneous mastocytoma	
New code		D47.093 Mastocytoma, unspecified	
New code		D47.098 Other mast cell neoplasms of uncertain behavior	
New code		D47.099 Mast cell neoplasms of uncertain behavior, unspecified Mast cell tumor NOS	
		D47.Z Other specified neoplasms of uncertain behavior of lymphoid, hematopoietic and related tissue	
New code		D47.Z8 Other histiocytic neoplasms of uncertain behavior Other histiocytic tumors of uncertain behavior	
Delete	D47.Z9 Other specified neoplasms of uncertain behavior of lymphoid, hematopoietic and related tissue Histiocytic tumors of uncertain behavior		
	Q82	Other congenital malformations of skin	
Revise Delete Add Add	Q82.2 <u>Pediatric cutaneous</u> mastocytosis <u>of newborn onset</u> <u>Urticaria pigmentosa</u> Congenital cutaneous mastocytosis Pediatric cutaneous mastocytosis of neonatal onset Excludes1:adult solitary mastocytoma (D47.028) extracutaneous mastocytoma (D47.097) malignant mastocytosis (C96.2-) mastocytoma NOS (D47.091) solitary mastocytoma (D47.012)		
New code	Q82.20 Cutaneous mastocytosis of newborn onset, unspecified Cutaneous mastocytosis of neonatal onset, unspecified		
New code	e Q82.21 Urticaria pigmentosa of newborn onset Congenital maculopapular cutaneous mastocytosis Congenital urticaria pigmentosa Maculopapular cutaneous mastocytosis of newborn onset Urticaria pigmentosa of neonatal onset Excludes1: adult urticaria pigmentosa (D47.020) urticaria pigmentosa NOS (with onset after newborn period) (D47.010)		

	ICD-10 Coordination and Maintenance Committee Meeting September 23-24, 2014
New code	Q82.22Diffuse cutaneous mastocytosis of newborn onset Congenital diffuse cutaneous mastocytosis Diffuse cutaneous mastocytosis of neonatal onset Excludes1:diffuse cutaneous mastocytosis NOS (with onset after newborn period) (D47.011)
New code	Q82.23Solitary mastocytoma of newborn onset Congenital solitary mastocytoma Solitary mastocytoma of neonatal onset Excludes1:solitary mastocytoma NOS (with onset after newborn period) (D47.012)
New code	Q82.29Other cutaneous mastocytosis of newborn onset Other congenital cutaneous mastocytosis Other cutaneous mastocytosis of neonatal onset Other cutaneous mastocytosis with onset as newborn
Changes to previous	March 2014 proposal at D89.4:
• •	March 2014 proposal at D89.4:
Changes to previous New subcategory	March 2014 proposal at D89.4: D89.4 Mast cell activation syndrome and related disorders
New	
New subcategory	D89.4 Mast cell activation syndrome and related disorders
New subcategory Add Add Revise	D89.4 Mast cell activation syndrome and related disorders Excludes1:adult cutaneous mastocytosis (D47.02-) adult systemic mastocytosis (D47.04) aggressive systemic mastocytosis (C96.2 <u>1</u>)
New subcategory Add Add Revise Revise	D89.4 Mast cell activation syndrome and related disorders Excludes1:adult cutaneous mastocytosis (D47.02-) adult systemic mastocytosis (D47.04) aggressive systemic mastocytosis (C96.2 <u>1</u>) <u>congenital</u> cutaneous mastocytosis (Q82.2 <u>-</u>)
New subcategory Add Add Revise Revise Revise	D89.4 Mast cell activation syndrome and related disorders Excludes1:adult cutaneous mastocytosis (D47.02-) adult systemic mastocytosis (D47.04) aggressive systemic mastocytosis (C96.2 <u>1</u>) <u>congenital</u> cutaneous mastocytosis (Q82.2 <u>-</u>) indolent systemic mastocytosis (D47.0 <u>41</u>)
New subcategory Add Add Revise Revise Revise Revise Add	D89.4 Mast cell activation syndrome and related disorders Excludes1:adult cutaneous mastocytosis (D47.02-) adult systemic mastocytosis (D47.04) aggressive systemic mastocytosis (C96.2 <u>1</u>) <u>congenital</u> cutaneous mastocytosis (Q82.2_) indolent systemic mastocytosis (D47.0 <u>41</u>) malignant mast cell neoplasm (C96.2-)
New subcategory Add Add Revise Revise Revise	D89.4 Mast cell activation syndrome and related disorders Excludes1:adult cutaneous mastocytosis (D47.02-) adult systemic mastocytosis (D47.04) aggressive systemic mastocytosis (C96.2 <u>1</u>) <u>congenital</u> cutaneous mastocytosis (Q82.2-) indolent systemic mastocytosis (D47.0 <u>41</u>) malignant mast cell neoplasm (C96.2-) malignant mastocytoma (C96.2 <u>9</u>)
New subcategory Add Add Revise Revise Revise Add Revise	D89.4 Mast cell activation syndrome and related disorders Excludes1:adult cutaneous mastocytosis (D47.02-) adult systemic mastocytosis (D47.04) aggressive systemic mastocytosis (C96.2 <u>1</u>) <u>congenital</u> cutaneous mastocytosis (Q82.2_) indolent systemic mastocytosis (D47.0 <u>41</u>) malignant mast cell neoplasm (C96.2-) malignant mastocytoma (C96.2 <u>9</u>) mast cell leukemia (C94.3-)
New subcategory Add Add Revise Revise Revise Revise Add	D89.4 Mast cell activation syndrome and related disorders Excludes1:adult cutaneous mastocytosis (D47.02-) adult systemic mastocytosis (D47.04) aggressive systemic mastocytosis (C96.2 <u>1</u>) <u>congenital</u> cutaneous mastocytosis (Q82.2 <u>-</u>) indolent systemic mastocytosis (D47.0 <u>41</u>) malignant mast cell neoplasm (C96.2-) malignant mastocytoma (C96.2 <u>9</u>) mast cell leukemia (C94.3-) mast cell sarcoma (C96.22)
New subcategory Add Add Revise Revise Revise Add Revise Add Revise	D89.4 Mast cell activation syndrome and related disorders Excludes 1: adult cutaneous mastocytosis (D47.02-) adult systemic mastocytosis (D47.04) aggressive systemic mastocytosis (C96.2 <u>1</u>) <u>congenital</u> cutaneous mastocytosis (Q82.2-) indolent systemic mastocytosis (D47.0 <u>41</u>) malignant mast cell neoplasm (C96.2-) malignant mastocytoma (C96.2 <u>9</u>) mast cell leukemia (C94.3-) mast cell sarcoma (C96.22) mastocytoma (D47.012, D47.028, D47.092-D47.093)
New subcategory Add Add Revise Revise Revise Add Revise Add Add	 D89.4 Mast cell activation syndrome and related disorders Excludes1: adult cutaneous mastocytosis (D47.02-) adult systemic mastocytosis (D47.04) aggressive systemic mastocytosis (C96.2<u>1</u>) <u>congenital</u> cutaneous mastocytosis (Q82.2-) indolent systemic mastocytosis (D47.0<u>41</u>) malignant mast cell neoplasm (C96.2-) malignant mastocytoma (C96.2<u>9</u>) mast cell leukemia (C94.3-) mast cell sarcoma (C96.22) mast cell sarcoma (C96.22) mastocytoma (D47.012, D47.028, D47.092-D47.093) mastocytosis (D47.010-D47.049, D47.090-D47.091, Q82.2-)
New subcategory Add Add Revise Revise Revise Add Revise Add Add Add	 D89.4 Mast cell activation syndrome and related disorders Excludes 1: adult cutaneous mastocytosis (D47.02-) adult systemic mastocytosis (D47.04) aggressive systemic mastocytosis (C96.21) congenital cutaneous mastocytosis (Q82.2-) indolent systemic mastocytosis (D47.041) malignant mast cell neoplasm (C96.2-) malignant mastocytoma (C96.22) mast cell leukemia (C94.3-) mast cell sarcoma (C96.22) mastocytoma (D47.012, D47.028, D47.092-D47.093) mastocytosis (D47.010-D47.049, D47.090-D47.091, Q82.2-) other mast cell neoplasms of uncertain behavior (D47.09-)
New subcategory Add Add Revise Revise Revise Add Revise Add Add	 D89.4 Mast cell activation syndrome and related disorders Excludes1:adult cutaneous mastocytosis (D47.02-) adult systemic mastocytosis (D47.04) aggressive systemic mastocytosis (C96.21) congenital cutaneous mastocytosis (Q82.2-) indolent systemic mastocytosis (D47.041) malignant mast cell neoplasm (C96.2-) malignant mastocytoma (C96.29) mast cell leukemia (C94.3-) mast cell sarcoma (C96.22) mastocytoma (D47.012, D47.028, D47.092-D47.093) mastocytosis (D47.010-D47.049, D47.090-D47.091, Q82.2-) other mast cell neoplasms of uncertain behavior (D47.09-) pediatric cutaneous mastocytosis (D47.01-)
New subcategory Add Add Revise Revise Revise Add Revise Add Add Add Add	 D89.4 Mast cell activation syndrome and related disorders Excludes 1: adult cutaneous mastocytosis (D47.02-) adult systemic mastocytosis (D47.04) aggressive systemic mastocytosis (C96.21) congenital cutaneous mastocytosis (Q82.2-) indolent systemic mastocytosis (D47.041) malignant mast cell neoplasm (C96.2-) malignant mastocytoma (C96.22) mast cell leukemia (C94.3-) mast cell sarcoma (D47.012, D47.028, D47.092-D47.093) mastocytosis (D47.010-D47.049, D47.090-D47.091, Q82.2-) other mast cell neoplasms of uncertain behavior (D47.09-)

INDEX MODIFICATIONS

Revise	Mastocytoma D47.0 - malignant C96.2 <u>9</u>
Revise	Nettleship's syndrome Q82.2 – see Urticaria, pigmentosa

26

Dyspareunia

Painful intercourse can occur for a variety of reasons — ranging from structural problems to psychological concerns. The persistent pain or discomfort associated with vaginal penetration is called dyspareunia.

The American Urological Association (AUA) is requesting new codes to align with a joint report on the terminology for female pelvic floor dysfunction which was published in 2009. The report combined input from two international organizations, the International Urogynecological Association (IUGA) and the International Continence Society (ICS). The publication has become a guide for standardized language and diagnoses terminology.

In the report, dyspareunia is further categorized as superficial (introital) and deep. Superficial (introital) dyspareunia is described as pain or discomfort on vaginal entry or at the vaginal introitus. Deep dyspareunia is described as pain or discomfort on deeper penetration (mid or upper vagina).

AUA is requesting the following new codes to identify the types of dyspareunia that are not currently represented in ICD-10-CM. AUA indicates unique codes are important, not only for population studies and research, but as the underlying etiology and treatment of each unique condition may differ.

TABULAR MODIFICATIONS

N94 Pain and other conditions associated with female genital organs and menstrual cycle

N94.1	Dyspareunia		
	Excludes1: psychogenic dyspareunia (F52.6)		

New code	N94.10	Unspecified dyspareunia
New code	N94.11	Superficial (introital) dyspareunia
New code	N94.12	Deep dyspareunia
New code	N94.19	Other specified dyspareunia

Incontinence

Urinary incontinence is a condition of involuntary loss of urine that is often bothersome and can adversely affect quality of life. An important aspect of urinary incontinence and sexual function is the symptom of coital incontinence. Coital incontinence is an involuntary loss of urine with coitus. Coital incontinence is the result of underlying pelvic floor dysfunction whose etiologies are multifactorial.

An involuntary loss of urine associated with a change of body position, for example, rising from a seated or lying position is called postural urinary incontinence.

The American Urological Association (AUA) is requesting new codes to align with a joint report on the terminology for female pelvic floor dysfunction published in 2009, combining the input of two international organizations, the International Urogynecological Association (IUGA) and the International Continence Society (ICS). The publication has become a guide for standardized language and diagnoses terminology.

AUA is requesting the following new codes for consistency and to uniquely identify the types of incontinence that are not currently represented in ICD-10-CM. AUA indicates unique codes are important, not only for population and research, but as the underlying etiology and treatment of each unique condition may differ.

N39		Other disorders of urinary system			
		N39.4 Other sp	ecified urinary incontinence		
		N39.42	Incontinence without sensory awareness		
Add			Insensible (urinary) incontinence		
		N39.49	Other specified urinary incontinence		
New Code			N39.491 Coital incontinence		
New Code			N39.492 Postural (urinary) incontinence		

Difficulties with micturition

Voiding dysfunction is a condition in which the bladder is not able to empty properly. Voiding dysfunction can be described by symptoms such as a need to immediately re-void soon after micturition, straining to void, and postmicturition leakage (involuntary passage of urine following the completion of micturition).

Having to take specific positions to be able to micturate spontaneously or to improve bladder emptying, for example, leaning forwards or backwards on the toilet seat or voiding in the semi-standing position is called position-dependent micturition.

The American Urological Association (AUA) is requesting new codes to align with a joint report on the terminology for female pelvic floor dysfunction published in 2009, combining the input of two international organizations, the International Urogynecological Association (IUGA) and the International Continence Society (ICS). The publication has become a guide for standardized language and diagnoses terminology.

AUA is requesting the following new codes for consistency and to uniquely identify these symptoms that are not currently represented in ICD-10-CM. AUA indicates unique codes are important, not only for population studies and research, but as the underlying etiology and treatment of each unique condition may differ.

TABULAR MODIFICATIONS

R39 Other and unspecified symptoms and signs involving the genitourinary system

R39.1 Other difficulties with micturition

R39.19	Other difficulties with micturition	
--------	-------------------------------------	--

New Code New Code New Code

- R39.191 Need to immediately re-void
- R39.192 Position dependent micturition
- R39.198 Other difficulties with micturition

Irritable Bowel Syndrome with Constipation

Functional gastrointestinal disorders (FGIDs) can affect any part of the gastrointestinal tract; they are disorders of how the GI tract works, not structural or biochemical abnormalities. Irritable bowel syndrome (IBS) is a chronic functional gastrointestinal disorder characterized by abdominal pain or discomfort associated with altered bowel habits. IBS is classified into subtypes based on the predominant alteration in stool form: IBS with constipation (IBS-C), IBS with diarrhea (IBS-D), some people have both (IBS-M for "mixed") or neither (IBS-U for "unspecified").

A symptom based diagnostic criteria, Rome III criteria, is considered the current standard for diagnosing FGIDs. According to the Rome III criteria, IBS is defined as recurrent abdominal pain or discomfort for at least 3 days per month in the past 3 months associated with 2 or more of the following: (1) improvement with defecation, (2) onset associated with a change in stool frequency, and/or (3) onset associated with a change in stool form.

IBS-C is estimated to affect 4.3% to 5.2% of the adult population in the United States.

Forest Laboratories, LLC is requesting the following new codes to identify and distinguish across subtypes, since diagnostic requirements and treatment options for IBS-D and IBS-C differ. Allowing for more specific codes would promote accurate disease identification, as well as align with the standard diagnostic criteria.

TABULAR MODIFICATIONS

New code	K58.1	Irritable bowel syndrome with constipation

Irritable bowel syndrome

New code K58.8 Other irritable bowel syndrome

K58

Chronic Idiopathic Constipation

Chronic idiopathic constipation (CIC) also known as functional constipation (FC) is a commonly occurring functional gastrointestinal disorder (FGID). CIC is characterized by infrequent bowel movements, hard or lumpy stools, straining, and a sensation of incomplete rectal evacuation.

A symptom based diagnostic criteria, Rome III criteria, is considered the current standard for diagnosing FGIDs. The Rome III criteria for FC requires the following criteria be fulfilled for the last 3 months and symptom onset at least 6 months prior to diagnosis: (1) two or more of the following: straining during at least 25% of bowel movements, lumpy or hard stools in at least 25% of bowel movements, sensation of incomplete evacuation in at least 25% of bowel movements, manual maneuvers to facilitate at least 25% of bowel movements, and fewer than three bowel movements per week; (2) loose stools rarely present without the use of laxatives; and (3) insufficient criteria for irritable bowel syndrome.

CIC is estimated to affect 12% to 19% of the population in the United States.

Forest Laboratories, LLC is requesting a new code for CIC, to achieve greater specificity and clinical detail. Allowing a more specific code would promote accurate disease identification, as well as align with the standard diagnostic criteria.

	K59	Other functional intestinal disorders		
		K59.0 Constipation		
New code		K59.04	Chronic idiopathic constipation	

Observation and evaluation of newborns for suspected conditions ruled out

It is not uncommon for a parent to seek medical care for a perceived problem with their newborn. Very often there isn't any specific condition and reassurance is all that is required. Currently ICD-10-CM does not have any way to uniquely capture suspected conditions ruled out as the reason for the encounter.

Currently in ICD-9-CM there are unique codes found in category V29, Observation and evaluation of newborns for suspected condition not found to show an encounter for a suspected condition in a newborn that is ruled out. In ICD-10-CM this can only be coded using codes in category P00, Newborn (suspected to be) affected by maternal conditions that may be unrelated to present pregnancy. Codes in this category suggest that they may include encounter of newborn for suspected condition not found, however it is of the opinion of the American Academy of Pediatrics (AAP) that category P00.- does not represent the same concepts as ICD-9-CM category V29.

In September 2013, The American Academy of Pediatrics originally submitted a proposal for unique set of codes be added to ICD-10-CM to more clearly capture this information however based on public comments, the proposal has been revised and is being resubmitted for reconsideration. It should also be noted that the codes currently proposed are not a direct walk over from ICD-9-CM.

EL A	P00	Newborn (suspected to be) affected by maternal conditions that may be unrelated to present pregnancy	
Add		Excludes 2: Encounter for observation of newborn for suspected diseases and conditions ruled out (Z05)	
New category	Z05	Encounter for observation and evaluation of newborn for suspected diseases and conditions ruled out	
		This category is to be used for newborns, within the neonatal period (the first 28 days of life), who are suspected of having an abnormal condition unrelated to exposure from the mother or the birth process , but without signs or symptoms, and which, after examination and observation, is ruled out.	
		Excludes 2: newborn observation for suspected condition, related to exposure from the mother or birth process (P00-P04)	
New Code		Z05.0 Observation and evaluation of newborn for suspected cardiac condition ruled out	
New code		Z05.1 Observation and evaluation of newborn for suspected infectious condition ruled out	
New code		Z05.2 Observation and evaluation of newborn for suspected neurological condition ruled out	

New code	Z05.3	Observation and evaluation of newborn for suspected respiratory condition ruled out
New subcategory	Z05.4	Observation and evaluation of newborn for suspected genetic, metabolic or immunologic condition ruled out
New Code		Z05.41 Observation and evaluation of newborn for suspected genetic condition ruled out
New Code		Z05.42 Observation and evaluation of newborn for suspected metabolic condition ruled out
New Code		Z05.43 Observation and evaluation of newborn for suspected immunologic condition ruled out
New Code	Z05.5	Observation and evaluation of newborn for suspected gastrointestinal condition ruled out
New Code	Z05.6	Observation and evaluation of newborn for suspected genitourinary condition ruled out
New subcategory	Z05.7	Observation and evaluation of newborn for suspected skin, subcutaneous, musculoskeletal and connective tissue condition ruled out
New Code		Z05.71 Observation and evaluation of newborn for suspected skin and subcutaneous tissue condition ruled out
New Code		Z05.72 Observation and evaluation of newborn for suspected musculoskeletal condition ruled out
New Code		Z05.73 Observation and evaluation of newborn for suspected connective tissue condition ruled out
New Code	Z05.8	Observation and evaluation of newborn for other specified suspected condition ruled out
New Code	Z05.9	Observation and evaluation of newborn for unspecified suspected condition ruled out

Gestational Carrier

The American Congress of Obstetricians and Gynecologists (ACOG) is proposing new codes for gestational carrier. Currently, there is no way to code this condition accurately. ACOG indicates that they currently use ICD-9-CM V26.9 Unspecified procreative management, to report this condition. ICD-10-CM does not have a unique code for this. Since this practice is becoming increasingly more common, ACOG is requesting unique codes to identify these patients. They suggest two new codes to uniquely identify patients undergoing counseling and evaluation prior to the assisted reproductive technology procedure, as well as a code to indicate pregnant patients who are gestational carriers.

The following tabular modifications are proposed:

	O09	Supervision of high risk pregnancy O09.8 Supervision of other high risk pregnancies O09.81 Supervision of pregnancy resulting from assisted reproductive technology
Add		Excludes2: gestational carrier status (Z33.3)
	Z31	Encounter for procreative management
New code		Z31.7 Encounter for procreative management and counseling for gestational carrier Excludes1: pregnant state, gestational carrier (Z33.3)
	Z33	Pregnant state
Add		Z33.1 Pregnant state, incidental Excludes1: pregnant state, gestational carrier (Z33.3)
New code		Z33.3 Pregnant state, gestational carrier Excludes1: encounter for procreative management and counseling for gestational carrier (Z31.7)

Minimally Invasive Surgical Procedures Converted to Open

The American Congress of Obstetricians and Gynecologists (ACOG) is requesting the addition of codes to indicate when a minimally invasive surgical procedure is converted to an open procedure. ICD-9-CM had specific diagnosis codes to indicate this and these are not currently in ICD-10-CM.

In 1997 the diagnosis code V64.4, Closed surgical procedure converted to open procedure was introduced to ICD-9-CM. In 2003 V64.4 was expanded to three codes to indicate specific types of closed procedures that were converted to open, as follows:

- V64.41 Laparoscopic surgical procedure converted to open procedure
- V64.42 Thoracoscopic surgical procedure converted to open procedure
- V64.43 Arthroscopic surgical procedure converted to open procedure

During development of ICD-10-CM these codes were not added because it was felt that these codes described procedures rather than a diagnosis. Additionally, there are guidelines for coding this using the procedure classifications. ACOG indicates that while procedure classifications may address the approach change, they feel that diagnosis codes reflecting this should be added to ICD-10-CM to describe the full service performed on a patient and to provide additional information about medical necessity linking for the additional services performed during these surgical encounters.

The minimally invasive surgical approach has increased in use in many specialties since the ICD-9-CM V64.4 code was first introduced. A brief literature search showed that about 10% of cases that start as a minimally invasive approach may need to be converted to an open approach, after the procedure has begun. Some reasons given for conversion included limited access to the surgical field (sometimes due to patient obesity or adhesions) and unexpected complications such as gall stone spillage in cholecystectomies. Although some of these conditions can be coded using existing ICD-10-CM codes sometimes the reason for the conversion of approach is one that does not have a code (low visual field or thick abdominal wall).

The following three options are offered to address this issue.

PROPOSED TABULAR MODIFICATIONS

Option 1: Add an inclusion term (and related indexing) to existing diagnosis code Z53.09, Procedure and treatment not carried out because of other contraindication.

Z53	Persons encountering health services for specific procedures and treatment, not carried out
	Z53.0 Procedure and treatment not carried out because of contraindication
	 Z53.09 Procedure and treatment not carried out because of other contraindication Condition encountered requiring conversion from minimally invasive to open approach

Option 2:

Add

Add a subcategory and new codes to ICD-10-CM category Z53, Persons encountering health services for specific procedures, not carried out. This placement and codes is equivalent to the ICD-9-CM (V64.4-) codes.

Z53	Persons o out	encount	ering health services for specific procedures and treatment, not carried
New subcategory	Z53.3 N	Minimall	ly invasive surgical procedure converted to open procedure
New code	Z	Z53.30	Unspecified minimally invasive surgical procedure converted to open
			procedure
New code	Z	Z53.31	Laparoscopic surgical procedure converted to open procedure
New code	Z	253.32	Thoracoscopic surgical procedure converted to open procedure
New code	Z	253.33	Arthroscopic surgical procedure converted to open procedure
New code	Z		Other specified minimally invasive surgical procedure converted to open procedure

Option 3:

Add new codes to each related body system chapter. This would be consistent with placement of other body system specific codes for intraoperative and postprocedural complications and disorders.

I97	Intraoperative and postprocedural complications and disorders of circulatory system, not elsewhere classified			
	I97.8	Other intraoperative and postprocedural complications and disorders of the circulatory system, not elsewhere classified		
New subcategory	I97.83 Other intraoperative disorders during circulatory system procedure			
New code		I97.831	Intraoperative condition encountered during circulatory system procedure requiring conversion from minimally invasive to open approach	

	ICD-10 Coordination and Maintenance Committee Meeting September 23-24, 2014		
J95	Intraoperative and postprocedural complications and disorders of respiratory system, not elsewhere classified		
	J95.8 Other intraoperative and postprocedural complications and disorders of respiratory system, not elsewhere classified		
New subcategory	J95.86 Other intraoperative disorders during respiratory system procedure		
New code	J95.861 Intraoperative condition encountered during respiratory system procedure requiring conversion from minimally invasive to open approach		
K91	Intraoperative and postprocedural complications and disorders of digestive system, not elsewhere classifiedK91.8 Other intraoperative and postprocedural complications and disorders of digestive system		
New subcategory	K91.88 Other intraoperative disorders during digestive system procedure		
New code	K91.881 Intraoperative condition encountered during digestive system procedure requiring conversion from minimally invasive to open approach		
N99	Intraoperative and postprocedural complications and disorders of genitourinary system, not elsewhere classified		
	N99.8 Other intraoperative and postprocedural complications and disorders of genitourinary system		
New subcategory	N99.88 Other intraoperative disorders during genitourinary system procedure		
New code	N99.881 Condition encountered during genitourinary surgery requiring conversion from minimally invasive to open approach		

3rd Degree Laceration during delivery

The American Congress of Obstetricians and Gynecologists (ACOG), through its collaborative hub- the Women's Health Registry Alliance, (reVITALize) initiative worked on the current classification of 3rd and 4th degree perineal lacerations and seeks to advance more robust data collection by moving toward agreement with the Royal College of Obstetricians and Gynaecologists.

In ICD-9-CM, obstetric trauma diagnosis codes include the following codes: 664.2 Third-degree perineal laceration [0,1,4] Perineal laceration, rupture, or tear (following episiotomy) involving: anal sphincter rectovaginal septum sphincter NOS Excludes: anal sphincter tear during delivery not associated with third-degree perineal laceration (664.6) that with anal or rectal mucosal laceration (664.3)

664.3 Fourth-degree perineal laceration

[0,1,4]

Perineal laceration, rupture, or tear as classifiable to 664.2 and involving also: anal mucosa rectal mucosa

In ICD-10-CM, the equivalent diagnosis codes are O70.2, Third degree perineal laceration during delivery, and O70.3, Fourth degree perineal laceration during delivery with equivalent inclusion terms.

The work group discussed the potential usefulness of additional codes for quality improvement and measurement purposes, specifically to promote more consistent documentation of lacerations. Coding improvements may be implemented well before electronic medical record systems are uniformly adopted in facilities. The benefits for documenting subclassifications within coding includes the ability to risk stratify and/or adjust for measurement as well as the ability to identify cases for chart review and quality improvement.

The reVITALize definition for perineal lacerations is:

- 1° Injury to perineal skin only
- 2° Injury to perineum involving perineal muscles but not involving anal sphincter
- 3° Injury to perineum involving anal sphincter complex
 - 3a: Less than 50% of External Anal Sphincter (EAS) thickness torn
 - 3b: More than 50% External Anal Sphincter (EAS) thickness torn
 - 3c: Both External Anal Sphincter (EAS) & Internal Anal Sphincter (IAS) torn

4° - Injury to perineum involving anal sphincter complex (External Anal Sphincter (EAS) & Internal Anal Sphincter (IAS)) and anal epithelium

The Royal College of Obstetricians and Gynaecologists subclassifies 3rd degree lacerations as grade III a, b or c depending on the severity of the trauma. In coordination with that effort and reVITALize, ACOG is proposing the following tabular modifications to expand the current ICD-10-CM codes for 3rd degree lacerations:

	O 70	Perineal laceration during delivery		
		O70.2 Third deg	ree perineal laceration during delivery	
New code		O70.20	Third degree perineal laceration during delivery, unspecified	
New code		O70.21	Third degree perineal laceration during delivery, IIIa Third degree perineal laceration during delivery with less than 50% of external anal sphincter (EAS) thickness torn	
New code		O70.22	Third degree perineal laceration during delivery, IIIb Third degree perineal laceration during delivery with more than 50% external anal sphincter (EAS) thickness torn	
New code		O70.23	Third degree perineal laceration during delivery, IIIc Third degree perineal laceration during delivery with both external anal sphincter (EAS) and internal anal sphincter (IAS) torn	

Ectopic Pregnancy

In 2001, at the request of the American Congress of Obstetricians and Gynecologists (ACOG), changes were made to ICD-9-CM to capture multiple gestation pregnancy with co-existing ectopic and intrauterine pregnancies. This was done to recognize that the increased incidence of this with the use of assisted reproductive technologies

These codes were not carried over to ICD-10-CM and ACOG is proposing that they are still necessary and should be added to this classification. The following changes are proposed to add these codes to category O00, Ectopic pregnancy.

	O 00	Ectopic pregnanc	у
		O00.0 Abdomina	al pregnancy
New code		O00.00	Abdominal pregnancy without intrauterine pregnancy Abdominal pregnancy NOS
New code		O00.01	Abdominal pregnancy with intrauterine pregnancy
		O00.1 Tubal pre	gnancy
New code		O00.10	Tubal pregnancy without intrauterine pregnancy Tubal pregnancy NOS
New code		O00.11	Tubal pregnancy with intrauterine pregnancy
		O00.2 Ovarian	pregnancy
New code		O00.20	Ovarian pregnancy without intrauterine pregnancy Ovarian pregnancy NOS
New code		O00.21	Ovarian pregnancy with intrauterine pregnancy
		O00.8 Other ecto	opic pregnancy
New code		O00.80	Other ectopic pregnancy without intrauterine pregnancy Other ectopic pregnancy NOS
New code		O00.81	Other ectopic pregnancy with intrauterine pregnancy
		O00.9 Unspecifi	ed ectopic pregnancy
New code		O00.90	Unspecified ectopic pregnancy without intrauterine pregnancy Ectopic pregnancy NOS
New code		O00.91	Unspecified ectopic pregnancy with intrauterine pregnancy

Contraceptive Initial Encounter and Surveillance Codes

The American Congress of Obstetricians and Gynecologists (ACOG) is proposing new codes for initial encounter and surveillance codes for vaginal ring hormonal contraceptive device and transdermal patch hormonal contraceptive device contraceptive methods. These are methods of contraception that are not currently uniquely represented in ICD-10-CM, but are often the reason for visit. Additionally, ACOG proposes adding inclusion terms for barrier contraception (diaphragm) at the existing subcategories Z30.01, Encounter for initial prescription of contraceptives and Z30.4, Encounter for surveillance of contraceptives.

The following tabular modifications at category Z30 are proposed:

	Z30	Encounter for contraceptive management		
		Z30.0 Encounter for general counseling and advice on contraception		
		Z30.01 Encounter for initial prescription of contraceptives		
Add		Encounter for initial prescription of barrier contraception		
Add		Encounter for initial prescription of diaphragm		
New code		Z30.015 Encounter for initial prescription of vaginal ring hormonal contraceptive		
New code		Z30.016 Encounter for initial prescription of transdermal patch hormonal contraceptive device		
		Z30.4 Encounter for surveillance of contraceptives		
Add		Encounter for surveillance of barrier contraception		
Add		Encounter for surveillance of diaphragm		
New code New code		Z30.44 Encounter for surveillance of vaginal ring hormonal contraceptive device Z30.45 Encounter for surveillance of transdermal patch hormonal contraceptive device		

Ovarian Cyst Laterality

The American Congress of Obstetricians and Gynecologists (ACOG) would like to propose new codes to capture laterality for ovarian cyst related codes. Laterality is not currently specified in ICD-10-CM in the codes for ovarian cyst which are located in category N83, Noninflammatory disorders of ovary, fallopian tube and broad ligament. This level of specificity is important for data capturing and additionally it would be beneficial to have laterality specified in these codes since different services might performed on each side depending on the disease process.

ACOG proposes the following changes to category N83 for inclusion of laterality for these conditions.

	N83	Noninflammatory disorders of ovary, fallopian tube and broad ligament		
		N83.0 Follic	ular cyst of ova	ary
New code		N83.0	0 Follicula	cyst of ovary, unspecified side
New code		N83.0		r cyst of right ovary
New code		N83.0		cyst of left ovary
		N83.1 Corpu	s luteum cyst	
New code		N83.1	0 Corpus lu	iteum cyst of ovary, unspecified side
New code		N83.1	1 Corpus lu	iteum cyst of right ovary
New code		N83.1	2 Corpus lu	ateum cyst of left ovary
		N83.2 Other	and unspecifie	ed ovarian cysts
		N83.2	-	ied ovarian cyst
New code			-	Unspecified ovarian cyst, right side
New code			N83.202	1 0
New code			N83.209	1 .
				Ovarian cyst, NOS
		N83.2	9 Other ova	arian cyst
New code			N83.291	Other ovarian cyst, right side
New code			N83.292	Other ovarian cyst, left side
New code			N83.299	Other ovarian cyst, unspecified side
		N83.3 Acqui	red atrophy of	ovary and fallopian tube
		N83.3		atrophy of ovary
New code			N83.311	Acquired atrophy of right ovary
New code			N83.312	Acquired atrophy of left ovary
New code			N83.319	Acquired atrophy of ovary, unspecified side
				Acquired atrophy of ovary, NOS

	ICD-10 Coordination and Maintenance Committee Meeting September 23-24, 2014
New code New code New code	 N83.32 Acquired atrophy of fallopian tube N83.321 Acquired atrophy of right fallopian tube N83.322 Acquired atrophy of left fallopian tube N83.329 Acquired atrophy of fallopian tube, unspecified side Acquired atrophy of fallopian tube, NOS
New code New code New code	 N83.33 Acquired atrophy of ovary and fallopian tube N83.331 Acquired atrophy of right ovary and fallopian tube N83.332 Acquired atrophy of left ovary and fallopian tube N83.339 Acquired atrophy of ovary and fallopian tube, unspecified side Acquired atrophy of ovary and fallopian tube, NOS
New code	 N83.4 Prolapse and hernia of ovary and fallopian tube N83.40 Prolapse and hernia of ovary and fallopian tube, unspecified side Prolapse and hernia of ovary and fallopian tube, NOS
New code New code	N83.41 Prolapse and hernia of right ovary and fallopian tubeN83.42 Prolapse and hernia of left ovary and fallopian tube
New code New code New code	 N83.5 Torsion of ovary, ovarian pedicle and fallopian tube N83.51 Torsion of ovary and ovarian pedicle N83.511 Torsion of right ovary and ovarian pedicle N83.512 Torsion of left ovary and ovarian pedicle N83.519 Torsion of ovary and ovarian pedicle, unspecified side Torsion of ovary and ovarian pedicle, NOS
New code New code New code	 N83.52 Torsion of fallopian tube N83.521 Torsion of right fallopian tube N83.522 Torsion of left fallopian tube N83.529 Torsion of fallopian tube, unspecified side Torsion of fallopian tube, NOS

Supervision of Pregnancy with History of Ectopic or Molar Pregnancy

The American Congress of Obstetricians and Gynecologists (ACOG) is proposing changes to subcategory O09.1, Supervision of high risk pregnancy with history of ectopic or molar pregnancy. They propose to separate the two conditions represented in this subcategory as they are totally distinct and require different patient management.

The following Tabular changes are proposed to subcategory O09.1, Supervision of high risk pregnancy with history of ectopic or molar pregnancy.

O09	Supervision of high risk pregnancy	
Revise	O09.1 Supervision of pregnancy with histo	ory of ectopic or molar pregnancy
Revise	O09.10 Supervision of pregnancy pregnancy, unspecified	ey with history of ectopic or molar I trimester
Revise		y with history of ectopic or molar
Revise		y with history of ectopic or molar
Revise		y with history of ectopic or molar
New subcategory	O09.A Supervision of pregnancy with histo	ory of molar pregnancy
New code	O09.A0 Supervision of pregnanc unspecified trimester	ey with history of molar pregnancy,
New code	L	y with history of molar pregnancy, first
New code	O09.A2 Supervision of pregnanc trimester	y with history of molar pregnancy, second
New code	O09.A3 Supervision of pregnanc trimester	y with history of molar pregnancy, third

Sarcopenia

A proposal to create a new code for sarcopenia was received from the Alliance for Aging Research. It is part of the Aging In Motion Coalition, which is a group of patient, caregiver, health and aging organizations pressing for greater awareness, regulatory consideration, and improved treatment of sarcopenia.

Sarcopenia as a specific condition was initially identified in 1989. Originally, it referred to the loss of muscle mass that occurs with age, and was seen as a characteristic state almost universal with aging. Over time however, clinical perspectives on sarcopenia have evolved. Particularly because loss of muscle mass by itself does not necessarily correlate with weakness or functional impairment, sarcopenia has now come to be defined as a clinically significant disorder based on distinct findings and functional issues.

The Foundation for the National Institutes of Health Sarcopenia Project recently published its findings of an evidence-based approach to criteria for the diagnosis of sarcopenia.¹ Together with the published findings of the European Working Group on Sarcopenia in Older Persons², and other national and international groups^{3,4,5}, a consensus has emerged based on clinically relevant thresholds. Although there are some regional variations in specific cut points, there is wide conceptual agreement on the base definition.

Sarcopenia is now defined as a combination of low muscle mass together with weakness causing functional problems. The degree of muscle mass is measured by appendicular lean mass (i.e., non-bone lean mass of the limbs), typically assessed by using dual-energy X-ray absorptiometry (DEXA). Strength level is measured using customary protocols for grip strength. Finally, functional issues focus on mobility impairment, using standard tests such as gait speed or the "timed up and go" test.

Patients with sarcopenia typically experience mobility limitations and other functional issues such as an inability to carry out activities of daily living. Low grip strength and slow gait speed are strongly correlated with decreased ability to recover from serious injury, falls, disability, hospital and nursing home admissions, and increased mortality. Conditions which may be associated with sarcopenia include hip fracture, bed rest with immobilization, chronic obstructive pulmonary disease, diabetes mellitus type 2, stroke, Parkinson's disease, and congestive heart failure. While all people lose muscle mass and strength as they age, some older adults may have accelerated loss of muscle and may develop sarcopenia without having any of these conditions.

Establishing a diagnosis of sarcopenia allows for interventions such as nutritional counseling, occupational therapy, and physical therapy such as resistance and strength training to improve muscle strength. It also allows for identification of individuals at risk for falls and future disability, for whom preventive measures may then be taken. Pharmacological interventions are also being considered.

References

1. Journals of Gerontology (Series A) Biological Sciences, Medical Sciences, May 2014, 69(5):547-594.

2. Sarcopenia: European Consensus on Definition and Diagnosis: Report of the European Working Group on Sarcopenia in Older People. *Age Ageing*. 2010;39(4):412-423.

3. Fielding RA, Vellas B et al. Sarcopenia: An Undiagnosed Condition in Older Adults. Current Consensus Definition: Prevalence, Etiology, and Consequences. International Working Group on Sarcopenia. *Journal of the American Medical Directors Association*, May 2011; 12(4):249-256.

4. Morley JE, Abbatecola AM, et al. Sarcopenia With Limited Mobility: An International Consensus. The Society on Sarcopenia, Cachexia, and Wasting Disorders Trialist Workshop. *Journal of the American Medical Directors Association*, July 2011; 12(6):403-409

5. Muscaritoli M, et al. (2010) Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) "cachexia-anorexia in chronic wasting diseases" and "nutrition in geriatrics". *Clinical Nutrition*, April 2010; 29 (2):154–159.

	M62 Other disorders of muscle
Add	M62.5 Muscle wasting and atrophy, not elsewhere classified Excludes1: <u>sarcopenia (M62.84)</u>
	M62.8 Other specified disorders of muscle
Add	M62.81 Muscle weakness (generalized) Excludes1: muscle weakness in sarcopenia (M62.84)
New code	M62.84 Sarcopenia
	R53 Malaise and fatigue
Add	R53.1 Weakness Excludes1: sarcopenia (M62.84)
Add	R54 Age-related physical disability Excludes1: <u>sarcopenia (M62.84)</u>

ICD-10-CM TABULAR OF DISEASES PROPOSED ADDENDA All proposed effective October 1, 2016

Revise Revise	C7A	Malignant neuro C7A.0 Maligna C7A.09	nt carcinoid	
Revise			C7A.096	Malignant carcinoid tumor of the hindgut unspecified
	C94	Other leukemia	-	
		C94.2 Acute m		
D		C94.20		karyoblastic leukemia not having achieved remission
Revise			Acute mega	karyoblastic leukemia with <u>failed</u> remission
	D3A	Benign neuroen		
		D3A.0 Benign		
- ·		D3A.09	-	inoid tumors of other sites
Revise			D3A.094	Benign carcinoid tumor of the foregut <u>unspecified</u>
Revise			D3A.095	Benign carcinoid tumor of the midgut <u>unspecified</u>
Revise			D3A.096	Benign carcinoid tumor of the hindgut <u>unspecified</u>
	D10	Benign neoplas	m of mouth a	nd pharynx
Revise		D10.3 Benign	neoplasm of o	other and unspecified parts of mouth
	E29	Testicular dysfu	inction	
Revise		Excludes1:		s syndrome (Q98.0- <u>Q98.1</u> , Q98.4)
	E50	Savual duatura	tion not due t	o a substance or known physiclogical condition
	Г32	F52.2 Sexual a		o a substance or known physiological condition
				ual arousal disorder
Delete		1 52.22	Frigidity	
	140	Condiamyanath	••	
Delete	I42	Cardiomyopath Excludes1:	•	rdiomyopathy (125.5)
Delete		Excludes1.		cardiomyopathy (090.3)
			1 1	
Add		Excludes2:		rdiomyopathy (I25.5)
Add				cardiomyopathy (O90.3)
			ventricular	hypertrophy (I51.7)
	I83	Varicose veins	of lower extr	emities
		I83.1 Varicos	e veins of lov	ver extremities with inflammation
Delete		Stasis de	ermatitis	

	ICD-10 Coordination and Maintenance Committee Meeting September 23-24, 2014
Add Add	 I87 Other disorders of veins I87.2 Venous insufficiency (chronic) (peripheral) Stasis dermatitis Excludes1: stasis dermatitis with varicose veins of lower extremities (I83.1-, I83.2-)
	 K91 Intraoperative and postprocedural complications and disorders of digestive system, not elsewhere classified K91.6 Intraoperative hemorrhage and hematoma of a digestive system organ or structure complicating a procedure
Revise	K91.61 Intraoperative hemorrhage and hematoma of a digestive system organ or structure complicating a digestive <u>system</u> procedure
Revise	Dermatitis and eczema (L20-L30) Excludes2: stasis dermatitis (183.1-183.2) (187.2)
Revise	L30 Other and unspecified dermatitis Excludes2:stasis dermatitis (183.1-183.2) (187.2)
Revise	 O42 Premature rupture of membranes O42.0 Premature rupture of membranes, onset of labor within 24 hours of rupture O42.02 Full-term premature rupture of membranes, onset of labor within 24 hours of rupture Premature rupture of membranes <u>at or after 37 completed weeks of gestation, onset of labor within 24 hours of rupture</u>
	 O42.1 Premature rupture of membranes, onset of labor more than 24 hours following rupture O42.12 Full-term premature rupture of membranes, onset of labor more than 24
Revise	hours following rupture Premature rupture of membranes <u>at or after 37</u> completed weeks of gestation, <u>onset of labor more than 24 hours following rupture</u> O42.9 Premature rupture of membranes, unspecified as to length of time between rupture
Revise	 and onset of labor O42.92 Full-term premature rupture of membranes, unspecified as to length of time between rupture and onset of labor Premature rupture of membranes <u>at or after 37 completed weeks of gestation, unspecified as to length of time between rupture and onset of labor</u>
Revise	Symptoms and signs involving the digestive system and abdomen (R10-R19) <u>Excludes2</u> : congenital or infantile pylorospasm (Q40.0) gestrointestingl hemorphage (K02.0 K02.2)
[Proposing to	gastrointestinal hemorrhage (K92.0-K92.2) o change the entire Excludes1 list to be an Excludes2 list)

ICD-10 Coordination and Maintenance Committee Meeting September 23-24, 2014 S49 Other and unspecified injuries of shoulder and upper arm S49.0 Physeal fracture of upper end of humerus S49.03 Salter-Harris Type III physeal fracture of upper end of humerus S49.031 Salter-Harris Type III physeal fracture of upper end of Revise humerus, right arm [Same changes will be made to make Salter-Harris consistent] S54 Injury of nerves at forearm level Injury of other nerves at forearm level S54.8 S54.8X Injury of other nerves at forearm level Revise S54.8X1 Injury of other nerves at forearm level, right arm Revise Revise S54.8X2 Injury of other nerves at forearm level, left arm S54.8X9 Injury of other nerves at forearm level, unspecified arm Revise T17 Foreign body in respiratory tract T17.3 Foreign body in larynx T17.32 Food in larynx Revise Bones in larynx T78 Adverse effects, not elsewhere classified T78.0 Anaphylactic reaction due to food Anaphylactic reaction due to tree nuts and seeds T78.05 Excludes2: anaphylactic reaction due to peanuts (T78.01) Revise T83 Complications of genitourinary prosthetic devices, implants and grafts T83.3 Mechanical complication of intrauterine contraceptive device T83.32 Displacement of intrauterine contraceptive device Add Missing string of intrauterine contraceptive device Y92 Place of occurrence of the external cause Y92.4 Street, highway and other paved roadways as the place of occurrence of the external Revise cause Z45 Encounter for adjustment and management of implanted device Z45.0 Encounter for adjustment and management of cardiac device Z45.01 Encounter for adjustment and management of cardiac pacemaker Encounter for adjustment and management of cardiac Add resynchronization therapy pacemaker (CRT-P) Z45.02 Encounter for adjustment and management of automatic implantable cardiac defibrillator Encounter for adjustment and management of cardiac Add resynchronization therapy defibrillator (CRT-D) Z95 Presence of cardiac and vascular implants and grafts Presence of cardiac pacemaker Z95.0 Add Presence of cardiac resynchronization therapy (CRT-P) pacemaker Excludes1: adjustment or management of cardiac device (Z45.0-) Add

Z95.8	Presence	e of other cardiac and vascular implants and grafts
	Z95.81	Presence of other cardiac implants and grafts
		Z95.810 Presence of automatic (implantable) cardiac defibrillator
		Presence of cardiac resynchronization therapy defibrillator
		(CRT-D)
		Presence of cardioverter-defribillator (ICD)

Add

Add

ICD-10-CM INDEX TO DISEASES and INJURIES PROPOSED ADDENDA All proposed effective October 1, 2016

Revise	Behavior - drug seeking <u>Z76.5</u>
	Climacteric (female) - see also Menopause - depression (single episode) F32.8
Add	recurrent episode F33.8
Add	- melancholia (single episode) F32.8
Add	recurrent episode F33.8
	Depression (acute) (mental) F32.9
A 11	- atypical (single episode) F32.8
Add	- recurrent episode F33.8- climacteric (single episode) F32.8
Add	recurrent episode F33.8
	- involutional (single episode) F32.8
Add	recurrent episode F33.8
	- menopausal (single episode) F32.8
Add	recurrent episode F33.8
	Dermatitis (eczematous) L30.9
	- stasis I87.2
Add	with
Add	varicose ulcer - see Varix, leg, with ulcer, with inflammation
Add	varicose veins - see Varix, leg, with, inflammation
Add	due to postthrombotic syndrome - see Syndrome, postthrombotic
	Disease
	- pelvis, pelvic
	inflammatory (female) N73.9
Add	chlamydial A56.11
	- Pick's G31.01 [F02.80]
Add	with behavioral disturbance G31.01 [F02.81] brain G31.01 [F02.80]
Add	with behavioral disturbance G31.01 [F02.81]
Add	of pericardium (pericardial pseudocirrhosis of liver) I31.1

	Eczema (acute) (chronic) (erythematous) (fissum) (rubrum) (squamous) (see also Dermatitis) L30.9
Revise	- stasis <u>187.2</u>
Add	with varicose veins - see Varix, leg, with, inflammation
	Embolism (multiple) (paradoxical) I74.9
	- obstetric (in) (pulmonary)
Revise	childbirth <u>O88.22</u>
Revise	pregnancy <u>088.21-</u>
Revise	puerperal <u>O88.23</u>
	Fracture, traumatic (abduction) (adduction) (separation) (see also Fracture, pathological) T14.8 - neck S12.9
	cervical vertebra S12.9
	seventh (displaced) S12.600
	specified type NEC (displaced) S12.690
Revise	<u>nondisplaced</u> S12.691
	sixth (displaced) S12.500
Revise	specified type NEC (displaced) S12.590
Revise	<u>nondisplaced</u> \$12.591 third (displaced) \$12.200
	specified type NEC (displaced) S12.290
Revise	<u>nondisplaced S12.291</u>
D .	Incarceration, incarcerated
Revise	<u>exomphalos</u> K42.0
	Involution, involutional - see also condition
Revise	- melancholia (recurrent episode) (single episode) F32.8
Add	recurrent episode F33.8
	Melancholia F32.9
	- climacteric (single episode) F32.8
Revise	recurrent episode <u>F33.8</u>
	- intermittent (single episode) F32.8
Add	recurrent episode <u>F33.8</u>
D	- involutional (single episode) F32.8
Revise	recurrent episode <u>F33.8</u>
Revise	 menopausal (single episode) F33.8 recurrent episode F33.8
100130	- stuporous (single episode) F32.8
Revise	recurrent episode <u>F33.8</u>

Add Revise	Menopause, menopausal (asymptomatic) (state) Z78.0 - depression (single episode) F32.8 - recurrent episode F33.8 - melancholia (single episode) F32.8 - recurrent episode <u>F33.8</u>
Revise	Newborn (infant) (liveborn) (singleton) Z38.2 - jaundice <u>P59.9</u>
Add	Obesity E66.9 - exogenous E66.09
Revise	Peritonitis K65.9 - with or following appendicitis <u>K35.3</u>
Revise	Personality (disorder) F60.9 - mixed (nonspecific) <u>F60.89</u>
Add Add Add Add Add Add Add	 Pick's disease or syndrome (brain) G31.01 [F02.80] - with behavioral disturbance G31.01 [F02.81] - brain G31.01 [F02.80] - with behavioral disturbance G31.01 [F02.81] - pericardium (pericardial pseudocirrhosis of liver) I31.1 syndrome - brain G31.01 [F02.80] - with behavioral disturbance G31.01 [F02.81] - of heart (pericardial pseudocirrhosis of liver) I31.1
Add	Pneumonia (acute) (double) (migratory) (purulent) (septic) (unresolved) J18.9 - MRSA (Methicillin resistant Staphylococcus aureus) J15.212
Revise Revise Revise	Pregnancy (single) (uterine) - see also Delivery and Puerperal - complicated by (care of) (management affected by) - premature rupture of membranes O42.90 with onset of labor within 24 hours O42.00 <u>at or after 37 weeks gestation O42.02</u> <u>after 24 hours O42.10</u> <u>at or after 37 weeks gestation O42.12</u> <u>at or after 37 weeks gestation O42.92</u>
Revise	Problem (with) (related to) - behavioral (adult) F69 drug seeking <u>Z76.5</u>

	Pseudohermaphroditism Q56.3 - female Q56.2
Revise	adrenal <u>(congenital)</u> E25.0
Add	Scoliosis (acquired) (postural) M41.9 - infantile – see Scoliosis, idiopathic, infantile
Add	- mantie – see Sconosis, hopatile, mantie
	Shock R57.9
	- anaphylactic T78.2
	due to food (nonpoisonous) T78.00
٨	nuts T78.05
Add	multiple types T78.05
	Stasis
Revise	- dermatitis <u>187.2</u>
Add	with
Add	varicose ulcer - see Varix, leg, with ulcer, with inflammation
Add	varicose veins - see Varix, leg, with, inflammation
Add	due to postthrombotic syndrome - see Syndrome, postthrombotic
	Stupor (catatonic) R40.1
Revise	- depressive <u>(single episode)</u> F32.8
Add	recurrent episode F33.8
	Sundroma saa alaa Digaaga
Revise	Syndrome – see also Disease - Bakwin-Krida Q78.5
Revise	- Danlos' <u>Q79.6</u>
Revise	- Soto <u>'s Q87.3</u>
Revise	- Pick's – see Disease, Pick's
	Threatened
	- labor (without delivery) O47.9
Revise	at or after 37 completed weeks of gestation O47.1
	Use (of)
Revise	- alcohol <u>Z72.89</u>
Revise	Volvulus (bowel) (colon) (duodenum) (intestine) K56.2
Add	- duodenum K31.5

ICD-10-CM External Cause of Injuries Index

Accident (to) X58- transport (involving injury to) V99- occupant (of)Revise- - minibus -- see Accident, transport, car pickup truck occupantRevise- - minivan -- see Accident, transport, car pickup truck occupant

ICD-10-CM Table of Neoplasms

Neoplasm - auditory Revise - canal (external) (skin) A81 C44.20- C79.2 D04.2- D23.2- D48.5 D49.2